MedTrace Logo

Effect of Different Local Anesthetic Volumes of Serratus Anterior Plan Block After Video-Assisted Thoracoscopic Surgery

NCT05255536 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-02-02

No results posted yet for this study

Summary

Video-assisted thoracic surgery (VATS) has become a common procedure in thoracic surgery. Severe postoperative pain may be encountered in patients undergoing VATS. Analgesic methods such as thoracic paravertebral block (TPVB), intercostal block, serratus anterior plane block (SAPB), and erector spinae plane block (ESPB) are widely used for VATS. Among these methods, ultrasound (US) guided TPVB is the most preferred method. In recent years, the frequency of application of plane blocks as a component of multimodal analgesia has been increased. ESPB and SAPB are some of them. In addition, SAPB application is increasing in patients who underwent thoracotomy and VATS. There is no consensus on the dose of analgesia in these studies. There are studies on volumes between 10 ml and 40 ml in the literature. In this study, it was aimed to compare the volumes of 20 ml and 30 ml containing local anesthetic at the same concentration (0.25% bupivacaine) of SAPB block to be performed with USG in patients who underwent VATS.

Conditions

  • Serratus Anterior Plane Block
  • Pain, Postoperative
  • Thoracic Surgery, Video-Assisted
  • Local Anesthetic

Interventions

PROCEDURE

Serratus Anterior Plan Block with 20 ml

Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.

PROCEDURE

Serratus Anterior Plan Block with 30 ml

Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.

Sponsors & Collaborators

  • Atatürk Chest Diseases and Chest Surgery Training and Research Hospital

    lead OTHER

Principal Investigators

  • Musa Zengin, MD · Atatürk Chest Diseases and Chest Surgery Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2024-04-15
Completion
2024-05-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05255536 on ClinicalTrials.gov